Recently, the US FDA updated the list of authorized artificial intelligence and machine learning (AI/ML) medical devices. This list is a barometer of the health status of the artificial intelligence industry, and updates show that the FDA is maintaining a rapid pace of authorization. In the past few years, the FDA’s AI authorization has maintained double-digit growth, which reflects the increasing number of submissions received by the FDA from AI developers. AI/ML medical equipment explosion In the past, the FDA usually updated the list of approved AI/ML devices once a year, but with the frequent changes and approvals of artificial intelligence technology, the FDA has increased the frequency of updating the list. This list update includes 61 new approvals, including products approved between March 31st and June 25th. Similar to previous updates, applications targeting radiology accounted for the majority of the new licenses, with 44 products on the list since ...
On September 4th, the Shanghai Stock Exchange terminated one IPO company: Shandong Branden Medical Equipment Co., Ltd. (hereinafter referred to as “Branden”). According to information, this was Branden’s voluntary withdrawal of its listing application, and the listing on the Science and Technology Innovation Board was terminated. Two major products support the banner of revenue Founded in 2003, Baibai An is a national high-tech enterprise dedicated to applying medical material modification technology to implantable medical devices, focusing on the research and development, production, and sales of biological and medical products. Through independent research and continuous innovation, Branden has formed a technology platform centered on medical material modification, precision machining, and digital diagnosis and treatment of vascular pathways. According to the prospectus, Branden is the first domestic enterprise to obtain the registration certificate for Class III medical device products of domestically produced Peripherally Inserted Central Catheters (PICCs), breaking the monopoly of imported ...
Recently, Beijing Pinchi Medical Equipment Co., Ltd. (hereinafter referred to as “Pinchi Medical”) completed the listing guidance registration and planned IPO at the Beijing Securities Regulatory Bureau, and the guidance institution is CICC. According to the counseling work arrangement, CICC plans to complete the counseling plan for Pinchi Medical in November and December this year, and apply to the Beijing Securities Regulatory Bureau for counseling acceptance. After the counseling is completed and accepted, Pinchi Medical may apply for an IPO. This is another brain pacemaker company that plans to go public through an IPO in 2023 after Jingyu Medical started filing for listing counseling. According to Smart Medical Equipment, so far, the only two local companies that mass-produce brain pacemakers have embarked on the road to IPO. Founded in 2008, Pinchi Medical is a high-tech enterprise specializing in the research and development, production and sales of a series of neuromodulatory ...
Recently, Beijing Pinchi Medical Equipment Co., Ltd. (hereinafter referred to as “Pinchi Medical”) completed its IPO counseling and registration with the Beijing Securities Regulatory Bureau, with the counseling agency being China International Capital Corporation (CICC). According to the coaching work arrangement, CICC plans to complete the coaching plan for Pinchi Medical in November December this year and apply for coaching acceptance from the Beijing Securities Regulatory Bureau. After completing the coaching acceptance, Pinchi Medical may apply for IPO. This is another brain pacemaker company planning to go public in 2023, following Jingyu Medical’s IPO guidance filing. According to reports from Smart Medical Devices, the only two local companies that mass produce brain pacemakers have now embarked on the path of IPO and planned to go public. Tsinghua endorsement, Pinchi Medical is aiming for IPO Pinchi Medical was founded in 2008 and is a high-tech enterprise specializing in the research, development, ...
Today (September 2nd), Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. (hereinafter referred to as “Yinghe Yimai”) announced the completion of an angel round financing of tens of millions of yuan, led by CICC Capital, marking a solid step forward for Yinghe Yimai in promoting the intelligentization of medical imaging. Multiple core products, focusing on intelligent medical imaging Yinghe Medical Pulse was founded in 2020 and is a continuous innovator in the field of medical imaging artificial intelligence based on its newly developed MIIA base model. In response to the current situation where medical imaging AI products are generally single disease, fragmented, and homogeneous, and cannot meet the actual needs of image reading work, Yinghe Medical Pulse is an emerging technology enterprise focused on medical imaging AI integration and research and development. It is committed to providing medical imaging auxiliary tools based on AI and statistical methods, as well as medical ...
Yuheng Pharmaceutical, founded by Zhu Jiman, the “Northeast Medicine King”, once became famous in the industry through continuous large-scale mergers and acquisitions of many pharmaceutical companies such as Auno Pharmaceutical and Shanghai Huatuo. In the end, it fell into a downturn due to frequent mergers and acquisitions. Recently, Yuheng Pharmaceutical handed in its first semi-annual report after the reorganization. The net profit attributable to the parent company in the first half of 2024 was 125 million yuan, a year-on-year increase of 342.39%, and a substantial increase in profits. How did Yuheng Pharmaceutical recover so quickly? We have to talk about PD-1. There are many competitors in the PD-1/L1 field. In June 2024, the listing application of Enlangsubai monoclonal antibody of Shijiazhuang Pharmaceutical Group was officially approved. So far, there are at least 15 PD-1/L1 monoclonal antibodies approved for listing in China. The PD-1/L1 track, which is being chased by major ...
Organiser: Easy Fairs Time: April 21 – 23, 2025 Address: Palais des expositions Pins Maritimes, Algiers 16000, Algeria Exhibition hall: Safex Expo Center Product range: Medical Products Zone: Medical diagnostic equipment & supplies, electronic medical devices & instruments, ambulance equipment, medical reagents & devices, etc. Hospital Supplies Zone: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical tools, medical clothing & bedding, emergency equipment, maternal & infant care equipment, disinfection equipment, etc. Laboratory Equipment Zone: Laboratory instruments & equipment, optical instruments & equipment, image analysis & processing systems, testing instruments & devices, laboratory renovation & upgradation technologies, consumables, and related software, etc. Pharmaceuticals Zone: Various novel drugs, traditional Chinese medicines, western medicines, traditional medicines, herbal medicines, Chinese medicinal health products, nutritional foods, etc. Pharmaceutical Machinery Zone: Pharmaceutical production equipment & technology, pharmaceutical packaging machinery, pharmaceutical packaging materials, production, cleaning, disinfection, and configuration systems for pharmaceuticals. About Maghreb Pharma Expo: The Maghreb ...
Recently, according to the Financial Times, Siemens Healthineers plans to acquire the diagnostic business of Advanced Accelerator Applications (AAA), a subsidiary of Novartis, for 200 million euros (approximately 1.593 billion yuan). AAA specializes in producing radioactive nuclide drugs, also known as nuclear drugs, for molecular imaging equipment PET (positron emission tomography). The transaction is expected to be completed in the fourth quarter. Expand business territory AAA was spun off from the European Organization for Nuclear Research (CERN) in 2002 and is an innovative radiopharmaceutical company focused on targeted radioligand therapy, precise radioligand imaging, and molecular imaging product development. Its main focus is on the development, production, and commercial application of Molecular Nuclear Medicine (MNM) products. On October 30, 2017, Novartis acquired the company for $3.9 billion to strengthen its radiopharmaceutical business capabilities, making AAA a subsidiary of Novartis. After years of development, AAA has built a pipeline covering various diagnostic ...
Today (August 26th), Ansukang Medical (Suzhou) Co., Ltd. (hereinafter referred to as “Ansukang Medical”) announced the completion of a new round of 100 million yuan financing. The round of financing is jointly invested by Taiping Innovation, Junlian Capital, and Shengjing Jiacheng. The funds raised from the financing will mainly be used for promoting the market of unmanned ultrasonic knives, building a new generation of energy platforms, and preparing production capacity. Founded in 2020, Ansukang Medical has been focusing on the research and development of innovative medical devices since its establishment. It is an innovative medical device company based on its own core technology system, committed to providing Chinese medical workers with better and more convenient medical devices. At present, the main product launched by Ansukang Medical is the new generation of non host ultrasonic knife, which is also the world’s first split type non host ultrasonic knife. Compared with similar ...
Pathology and tissue analysis are areas poised for transformative advancements. Drug developers and clinicians currently depend on long-established methods for crucial tasks such as diagnosing diseases, quantifying biomarkers, and predicting therapeutic responses. While there have been attempts to innovate by digitizing specimens and adding multiple markers to a single slide, there are still limitations, including the analysis of less than 1% of tissue samples and the inability to depict complex tissue architectures and cellular interactions that are only visible in three dimensions. 3D imaging technology captures significantly more data than traditional slide-based methods by digitizing whole biopsy specimens rather than just thin slices.Artificial intelligence (AI) and machine learning algorithms play a crucial role in quantifying relevant biomarkers and identifying areas for more detailed pathologist examination. Now, a pioneering 3D spatial biology platform can digitize entire tissue specimens quickly and non-destructively while providing AI-enabled quantitative analysis. This technology enhances the precision ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.